ClinicalTrials.gg
CompletedNCT05940428Updated Jun 12, 2026

A Study of ASKG712 in Patients With Diabetic Macular Edema

A Phase 1 interventional study of ASKG712 in Diabetic Macular Edema, sponsored by Visara, Inc.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Visara, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.

Enrollment
62nd of 65
10 · median 140
Started
2023
with 10 others
Phase 1
9 of 72
4 open now
Registered
48th of 72
by date

Among the 72 studies in Macular Edema with a site in China, this one is the 62nd largest by enrollment of the 65 interventional ones that give a count, is one of 11 that started in 2023, is one of 9 in phase 1, and was the 48th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Macular Edema with a site in China, or all of them as a file.
02

Study summary

This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema (DME).

Read the detailed description

Part 1 of this study is a multicenter, open-label, sequentially, multiple-dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 in patients with DME. Patients will be sequentially enrolled into four different dose-level cohorts following accelerated titration combined with the traditional "3+3" design.

Part 2 of this study was planned to be a multicenter, open-label, sequentially, dose-expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 in patients with DME. Part 2 was not initiated due to a strategic decision by the sponsor not related to safety or efficacy.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  2. of less than or equal to 12%
  3. For women of : agreement to use acceptable methods during the treatment period and for at least 90 days after the final dose of study treatment
  4. Ability and willingness to undertake all scheduled visits and assessments
  5. Macular thickening secondary to DME involving the center of the fovea
  6. Decreased visual acuity attributable primarily to DME

Exclusion criteria

Exclusion Criteria:

  1. History of allergy or current allergic response to ASKG712 or fluorescein
  2. Diseases that affect intravenous injection and venous blood sampling
  3. Uncontrolled blood pressure
  4. Systemic diseases
  5. Previous anti-VEGF drug treatment
  6. Currently pregnant or breastfeeding, or intend to become pregnant during the study
  7. Any uncontrolled clinical disorders
  8. Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
  9. History of intraocular or periocular treatment in the study eye
  10. Uncontrolled previous or current glaucoma in the study eye
  11. Previous intraocular operations in the study eye
  12. Active intraocular or periocular infection or active intraocular inflammation in the study eye
  13. History of uveitis in either eye
  14. Other protocol-specified inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    ASKG712

    Multiple doses of ASKG712 by intravitreal injection

    Biological: ASKG712

Interventions

  • BiologicalASKG712

    ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

    Also known as: AM712, VIS-101

06

What researchers measure

Primary outcomes

  1. Incidence of ocular adverse events (AEs) of the study eyes

    Any relevant ocular observations derived from best corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, ophthalmoscopy, optical coherence tomography (OCT), fundus photography, and angiography

    Time frame: 24 weeks

  2. Incidence of non-ocular AEs

    Any clinical safety observations assessed by physical examination, vital signs, electrocardiograph (ECG) and clinical laboratory tests

    Time frame: 24 weeks

Secondary outcomes

  1. Area under the concentration time curve (AUC)

    To evaluate the systemic pharmacokinetics of ASKG712 in patients with DME

    Time frame: 24 weeks

  2. Maximum plasma concentration (Cmax)

    To evaluate the systemic pharmacokinetics of ASKG712 in patients with DME

    Time frame: 24 weeks

  3. Incidence of Anti-Drug Antibody (ADA)

    To evaluate the immunogenicity of ASKG712 in patients with DME

    Time frame: 24 weeks

  4. Change From Baseline in BCVA in the Study Eye Over Time

    To evaluate the efficacy of ASKG712 in patients with DME

    Time frame: 24 weeks

07

Study locations

1 site
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make IPD or supporting information available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2024, 11 months.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2023
First posted
Jul 11, 2023
StartActual
Oct 23, 2023
Primary completionActual
Oct 21, 2024
CompletionActual
Oct 21, 2024
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05940428
Lead sponsor
Visara, Inc.
Collaborators
Suzhou Aosaikang Biopharmaceutical Co., Ltd., AskGene Pharma, Inc.
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Oct 23, 2023
Primary completion
Oct 21, 2024
Completion
Oct 21, 2024
Last update
Jun 12, 2026

Study contacts

Youxin Chen, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion